TY  - JOUR
T1  - Pharmaceutical Formulation as a Dynamic System Linking Molecular Stability, Process History, Manufacturability, and In-Use Performance throughout the Product Lifecycle
A1  - Rafael Mendoza
A1  - Isabela Cruz
A1  - Carlos Lopez
JF  - International Journal of Pharmaceutical Research and Allied Sciences
JO  - Int J Pharm Res Allied Sci
SN  - 2277-3657
Y1  - 2025
VL  - 14
IS  - 2
DO  - 10.51847/LRzZlfShUW
SP  - 12
EP  - 22
N2  - Pharmaceutical formulations are commonly described through composition, manufacturing specifications, critical quality attributes, and stability endpoints. Although these descriptions are necessary, they may inadequately represent products whose molecular organization, physical state, processability, release behavior, and in-use performance depend on the sequence of conditions experienced throughout the product lifecycle. This Original Dynamic-Systems Theory Article proposes that a pharmaceutical formulation should be conceptualized as a path-dependent system in which current behavior emerges from the interaction of nominal composition, evolving state variables, manufacturing history, environmental exposure, administration conditions, and patient handling. The theory distinguishes formulation from dosage form, formulation stability from fixed shelf-life description, process design from isolated unit-operation settings, and manufacturability from endpoint conformity. It introduces a formulation-state vector, transition operators, process memory, observation variables, performance domains, validation gates, and lifecycle-update rules. Molecular interactions and physical-state evolution are connected conceptually with manufacturing transitions, storage and transport, product–container and product–device interfaces, administration, and real-world use. Patient handling is incorporated as a conditional performance domain without equating acceptability or usability with adherence, bioavailability, safety, or therapeutic effectiveness. Model validation requires comparison with simpler static representations, deliberately varied histories, orthogonal state measurements, challenge testing, uncertainty analysis, external evaluation, and monitoring after material, process, site, equipment, packaging, or use-context changes. The proposed theory is an original conceptual synthesis rather than an empirically validated prediction system. Its intended contribution is to organize testable explanations of when process history matters, how it may propagate, which states require observation, and where formulation-level inference must stop before manufacturing, clinical, regulatory, or implementation decisions are made.
UR  - https://ijpras.com/article/pharmaceutical-formulation-as-a-dynamic-system-linking-molecular-stability-process-history-manufac-9vwezgoii9jpenk
ER  -